Orchard Capital Management LLC cut its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) by 73.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,826 shares of the biopharmaceutical company’s stock after selling 185,000 shares during […]
/PRNewswire/ Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency.
Colin Roskey, JD, a health care lawyer and former federal health official, has been appointed executive director of Kidney Care Partners, according to a press release.At the helm at Kidney Care Partners (KCP), Roskey will lead a coalition of more than 30 organizations that represent patient advocates, physician and health professional groups, dialysis providers, researchers and
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the recipient of a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 4,500,000 shares, a drop of 20.8% from the April 15th total of 5,680,000 shares. Based on an average daily volume of 1,880,000 shares, the […]
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, MarketWatch Earnings reports. Akebia Therapeutics had a negative net margin of 31.63% and a negative return on equity of 279.65%. The business […]